{"id":55803,"date":"2026-01-29T20:10:51","date_gmt":"2026-01-29T12:10:51","guid":{"rendered":"https:\/\/flcube.com\/?p=55803"},"modified":"2026-01-29T20:10:52","modified_gmt":"2026-01-29T12:10:52","slug":"micurx-mrx-5-gets-fda-nod-for-phase-ii-ntm-lung-disease-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55803","title":{"rendered":"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study"},"content":{"rendered":"\n<p><strong>MicuRx Pharmaceuticals Inc.<\/strong>, (<a href=\"https:\/\/www.google.com\/finance\/quote\/688373:SHA\">SHA: 688373<\/a>) a Sino\u2011US biopharmaceutical company, announced it has received approval from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> to initiate a <strong>Phase\u202fIIa clinical study<\/strong> for <strong>MRX-5<\/strong> in <strong>non\u2011cavitary lung disease<\/strong> caused by <strong>Mycobacterium abscessus complex infections<\/strong>. The drug previously received <strong>Orphan Drug Designation<\/strong> in <strong>December\u202f2024<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-drug-profile\">Regulatory Milestone &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>MicuRx Pharmaceuticals Inc. (Sino\u2011US)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>MRX-5 (benzoborazole\u2011class antibacterial)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Non\u2011cavitary lung disease from Mycobacterium abscessus complex<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>FDA Phase\u202fIIa clinical trial authorization<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Novel antibacterial targeting Non\u2011tuberculous Mycobacteria (NTM)<\/td><\/tr><tr><td><strong>Previous Milestone<\/strong><\/td><td>Orphan Drug Designation (Dec\u202f2024)<\/td><\/tr><tr><td><strong>Clinical Progress<\/strong><\/td><td>Phase\u202fI completed in Australia; China trials ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-market-need\">Mechanism of Action &amp; Market Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Class:<\/strong> MRX-5 is a <strong>benzoborazole\u2011class antibacterial<\/strong> designed to treat NTM infections, particularly <strong>Mycobacterium abscessus<\/strong>, which is <strong>intrinsically resistant<\/strong> to most antibiotics<\/li>\n\n\n\n<li><strong>Current Treatment Gap:<\/strong> Existing NTM therapy relies on <strong>multidrug regimens<\/strong> with <strong>long treatment durations<\/strong>, <strong>drug resistance<\/strong>, <strong>suboptimal efficacy<\/strong>, and <strong>numerous adverse reactions<\/strong><\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> MRX-5 demonstrates <strong>good antibacterial activity<\/strong> against common NTM pathogens including M. abscessus, with favorable safety and pharmacokinetic profiles in animal and human studies<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> No <strong>specific, highly effective anti\u2011M. abscessus drug<\/strong> currently exists, creating a significant market opportunity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NTM Market:<\/strong> Global NTM treatment market valued at <strong>$850\u202fmillion<\/strong> : in 2025, projected to exceed <strong>$1.5\u202fbillion<\/strong> : by 2030 driven by rising infection rates and limited therapeutic options<\/li>\n\n\n\n<li><strong>Orphan Drug Advantage:<\/strong> Orphan status provides <strong>7\u2011year market exclusivity<\/strong> in the US, tax credits, and expedited regulatory pathway<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>$300\u2013500\u202fmillion<\/strong> : peak annual sales for MRX-5 if approved, based on addressing a critical gap in NTM therapy<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Phase\u202fIIa approval validates MicuRx\u2019s platform for hard\u2011to\u2011treat infections; positions company for potential global partnership<\/li>\n\n\n\n<li><strong>Clinical Pathway:<\/strong> Phase\u202fIIa trial design will evaluate efficacy and safety in M. abscessus lung disease patients; results expected <strong>H2\u202f2027<\/strong><\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Trial initiation planned for <strong>Q2\u202f2026<\/strong>; China trials will support parallel NMPA filing strategy<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, market potential, and regulatory pathways for MRX-5. Actual results may differ due to clinical trial outcomes, competitive dynamics, and FDA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688373_20260129_PYG8.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688373_20260129_PYG8.\"><\/object><a id=\"wp-block-file--media-0541d431-66fe-42ea-8d54-ee7c3614ce37\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688373_20260129_PYG8.pdf\">688373_20260129_PYG8<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/688373_20260129_PYG8.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0541d431-66fe-42ea-8d54-ee7c3614ce37\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino\u2011US biopharmaceutical company, announced it has received approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55805,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,279,1102],"class_list":["post-55803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-micurx-pharmaceuticals","tag-sha-688373"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino\u2011US biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase\u202fIIa clinical study for MRX-5 in non\u2011cavitary lung disease caused by Mycobacterium abscessus complex infections. The drug previously received Orphan Drug Designation in December\u202f2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55803\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study\" \/>\n<meta property=\"og:description\" content=\"MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino\u2011US biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase\u202fIIa clinical study for MRX-5 in non\u2011cavitary lung disease caused by Mycobacterium abscessus complex infections. The drug previously received Orphan Drug Designation in December\u202f2024.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55803\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T12:10:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-29T12:10:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2905.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study\",\"datePublished\":\"2026-01-29T12:10:51+00:00\",\"dateModified\":\"2026-01-29T12:10:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2905.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"MicuRx Pharmaceuticals\",\"SHA: 688373\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55803#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55803\",\"name\":\"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2905.webp\",\"datePublished\":\"2026-01-29T12:10:51+00:00\",\"dateModified\":\"2026-01-29T12:10:52+00:00\",\"description\":\"MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino\u2011US biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase\u202fIIa clinical study for MRX-5 in non\u2011cavitary lung disease caused by Mycobacterium abscessus complex infections. The drug previously received Orphan Drug Designation in December\u202f2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55803\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2905.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2905.webp\",\"width\":1080,\"height\":608,\"caption\":\"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55803#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study - Insight, China&#039;s Pharmaceutical Industry","description":"MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino\u2011US biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase\u202fIIa clinical study for MRX-5 in non\u2011cavitary lung disease caused by Mycobacterium abscessus complex infections. The drug previously received Orphan Drug Designation in December\u202f2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55803","og_locale":"en_US","og_type":"article","og_title":"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study","og_description":"MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino\u2011US biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase\u202fIIa clinical study for MRX-5 in non\u2011cavitary lung disease caused by Mycobacterium abscessus complex infections. The drug previously received Orphan Drug Designation in December\u202f2024.","og_url":"https:\/\/flcube.com\/?p=55803","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-29T12:10:51+00:00","article_modified_time":"2026-01-29T12:10:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2905.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55803#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55803"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study","datePublished":"2026-01-29T12:10:51+00:00","dateModified":"2026-01-29T12:10:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55803"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55803#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2905.webp","keywords":["Clinical trial approval \/ initiation","MicuRx Pharmaceuticals","SHA: 688373"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55803#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55803","url":"https:\/\/flcube.com\/?p=55803","name":"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55803#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55803#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2905.webp","datePublished":"2026-01-29T12:10:51+00:00","dateModified":"2026-01-29T12:10:52+00:00","description":"MicuRx Pharmaceuticals Inc., (SHA: 688373) a Sino\u2011US biopharmaceutical company, announced it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase\u202fIIa clinical study for MRX-5 in non\u2011cavitary lung disease caused by Mycobacterium abscessus complex infections. The drug previously received Orphan Drug Designation in December\u202f2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55803#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55803"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55803#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2905.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2905.webp","width":1080,"height":608,"caption":"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55803#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2905.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55803"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55803\/revisions"}],"predecessor-version":[{"id":55806,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55803\/revisions\/55806"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55805"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}